Skip to content

Study on the mechanism and experimental diagnostic value of QSOX1 involved in lipid transport in preeclampsia

Study on the mechanism and experimental diagnostic value of QSOX1 involved in lipid transport in preeclampsia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061744
Enrollment
Unknown
Registered
2022-07-02
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Interventions

Preeclampsia:No

Sponsors

Guangzhou Women's and children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: The admission diagnosis of preeclampsia is in accordance with the guidelines for pregnancy induced hypertension diseases of Chinese Medical Association - 2020 edition formulated by the obstetrics and Gynecology branch of Chinese Medical Association: Preeclampsia: after 20 weeks of pregnancy, the systolic blood pressure = 140 mmHg and / or diastolic blood pressure = 90 mmHg, accompanied by any of the following items: urinary protein quantity = 0.3 g / 24 h, or urinary protein / creatinine ratio = 0.3, Or random urinary protein = + (inspection method for unconditional protein quantification); There is no proteinuria, but any of the following organs or systems are involved: heart, lung, liver, kidney and other important organs, or abnormal changes of blood system, digestive system and nervous system, placenta and fetus are involved, etc. Preeclampsia can also occur postpartum.

Exclusion criteria

Exclusion criteria: Exclusion criteria (any of the following): ? insufficient diagnostic evidence of pregnancy induced hypertension in medical history; ? No 24-hour urine protein test record before delivery; ? Incomplete laboratory and auxiliary examination; ? Patients with medical diseases with proteinuria as clinical manifestation (such as systemic lupus erythematosus, kidney disease, antineutrophil cytoplasmic antibody associated vasculitis, etc.)

Design outcomes

Primary

MeasureTime frame
Preeclampsia;triglyceride;HDL;LDL;quiescin sulfhydryl oxidase 1;

Countries

China

Contacts

Public ContactHu Yanwei
ywhu0618@163.com020-38076254

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026